Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | GLA | P06280 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | CASP1 | P29466 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588356 | 0.91 | KMT2A (0.50) | KMT2AACACBHDAC3HDAC4HDAC1 | |
| SCHEMBL30587446 | 0.90 | HDAC3 (0.48) | KMT2AACACBHDAC3HDAC4HDAC1 | |
| SCHEMBL23928855 | 0.90 | HDAC3 (0.48) | KMT2AACACBHDAC3HDAC4HDAC1 | |
| SCHEMBL21467195 | 0.88 | KMT2A (0.59) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3494576 | 0.88 | KMT2A (0.62) | KMT2AACACBHDAC3HDAC4HDAC1 | |
| SCHEMBL3494575 | 0.88 | KMT2A (0.62) | KMT2AACACBHDAC3HDAC4HDAC1 | |
| SCHEMBL471290 | 0.88 | KMT2A (0.74) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1690779 | 0.87 | HSD11B1 (0.60) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3490895 | 0.87 | KMT2A (0.61) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL308621 | 0.87 | KMT2A (0.61) | KMT2AHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595989-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| EP-2097420-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065508-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | KMT2A 2243/4885ACACB 3/4885HDAC3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.